The Gulls Eggs Luncheon 2017

The 29th Gulls’ Eggs Luncheon, held on Tuesday 9th May 2017, at Merchant Taylors’ Hall, generously supported by headline sponsor CRUX Asset Management, has raised over £77,000 for The Cure Parkinson’s Trust (CPT).

Over 600 wealth management professionals enjoyed The Gulls’ Eggs Luncheon, a unique networking event which has developed a loyal following over 29 years, and is now a firmly established event within the City’s social calendar.

The Gulls’ Eggs Luncheon includes servings of ethically sourced gulls’ eggs, a delicacy only available for a few weeks each year, as well as traditional accompaniments, including smoked salmon and delicious cheese.

“We are very grateful for the wide and substantial support that this crucial event in aid of The Cure Parkinson’s Trust has received”

commented Rupert Phelps, Chairman of the Gulls’ Eggs Committee.

“It is wonderful to see both perennial supporters and newer faces now coming every year. In addition to really strong attendance, the sponsors and advertisers have come together to make a truly significant contribution to the critical research work of The Cure Parkinson’s Trust.”

President and Co-Founder of The Cure Parkinson’s Trust Tom Isaacs said. “This is the second year we have been fortunate enough to be the sole beneficiaries of The Gulls’ Eggs Luncheon and once again we were amazed by the generosity of those who attended. The funds raised will be allocated to our cutting edge research programme which continues to generate ground-breaking science and prospective new treatments which have the capacity to slow, stop or even reverse Parkinson’s.”

Latest

Researchers at the Michael J Fox Foundation recently announced that SURE-PD3, a Phase III clinical trial evaluating the potential of Inosine to slow Parkinson's progression, will end earlier than planned...

Related

Researchers at the Michael J Fox Foundation recently announced that SURE-PD3, a Phase III clinical trial evaluating the potential of Inosine to slow Parkinson's progression, will end earlier than planned...

When misfolded, the protein alpha-synuclein becomes toxic to neurons and is a key pathological culprit in Parkinson’s. It is therefore an important target for disease-modification. Immunotherapy in Parkinson's attempts to use immune cells, and specifically the antibodies they generate, to target misfolded alpha-synuclein to inactivate it.

Soania Mathur was, like former President of CPT Tom Isaacs, diagnosed with Young Onset Parkinson's at just 27. For Soania, Tom’s core principles of supporting people with Parkinson’s in becoming active participants in the search for better treatments, key to finding a cure.

Researchers at the Johns Hopkins School of Medicine have published a research report that points not only towards a specific pathway of neurodegeneration for Parkinson's, but also highlights a therapeutic target for which clinically-approved drugs are already available.

When cells in the body become unwell or injured, they release proteins that inform the body of their stricken situation. These activate the release of further signalling proteins called inflammasomes...

A Special Issue of the European Journal of Neuroscience in memory of late President and Co-founder Tom Isaacs has been compiled by NECTAR and this article by Tom's wife Lyndsey heralds this collaboration...

The human appendix was long considered functionless and a bit of an oddity. Some people even thought of it as an accident of evolution. More recently, however, our ideas regarding the appendix have changed. And a new study published this week suggests that the appendix may even be influential in some cases of Parkinson's.

Most read

In a major breakthrough for the treatment of Parkinson's, researchers working with laboratory rats show it is possible to make dopamine cells from embryonic stem cells and transplant them into the brain.

Our international Linked Clinical Trials initiative (LCT) identifies potential new treatments to slow, stop or reverse Parkinson’s disease by 'repurposing' or repositioning drugs that are approved to treat other conditions.

When diagnosed, people with Parkinson’s have often had the disease for years and have lost over half of the dopamine producing cells in their brain. Now scientists are searching for a way to replace these nerve cells.

The study, published in The Lancet and funded by The Michael J. Fox Foundation for Parkinson’s Research (MJFF), supported by CPT found that people with Parkinson’s treated with Exenatide for one year performed better in motor tests than those on placebo.